Clinical trial · Observational
Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
A Pilot Study for the Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance)
NCT07570056CI-TRIAL-00120784not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this project is to test non-invasive, painless skin electrical bioimpedance (BioZ) measurements as an adjunctive biomarker to standard bone marrow biopsies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bioimpedance (BioZ) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with Suspected or AML or MDS
- description
- BioZ measurements will take about 1 minute to complete. The measurement will be completed 3 times.
- interventionNames
- Diagnostic Test: Bioimpedance (BioZ)
Primary outcomes (1)
- measure
- Correlate BioZ findings with Pathologic Results
- timeFrame
- up to one day
- description
- The primary outcome measure of this study is to correlate BioZ findings with pathologic results from bone marrow biopsies with AML or MDS.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspected or confirmed diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and undergoing a bone marrow biopsy. * Age 18 or older. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. Exclusion Criteria: * Study prospect that has an electronic implant (cardiac, neurological, sensory, prosthetic implants with an electronic component. Also monitoring and drug delivery systems.) * Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study. * Pregnant women * Inability to understand and/or speak the English or Spanish language.
References
Publications (6)
- BACKGROUNDTalati C, Sweet K. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leuk Res. 2018 Oct;73:58-66. doi: 10.1016/j.leukres.2018.09.001. Epub 2018 Sep 8. PMID 30223250
- BACKGROUNDBain BJ. Bone marrow biopsy morbidity: review of 2003. J Clin Pathol. 2005 Apr;58(4):406-8. doi: 10.1136/jcp.2004.022178. PMID 15790706
- BACKGROUNDAndreasen N, Crandall H, Brimhall O, Miller B, Perez-Tamayo J, Martinsen OG, Kauwe SK, Sanchez B. Skin Electrical Resistance as a Diagnostic and Therapeutic Biomarker of Breast Cancer Measuring Lymphatic Regions. IEEE Access. 2021;9:152322-152332. doi: 10.1109/access.2021.3123569. Epub 2021 Oct 27. PMID 34888126
- BACKGROUNDLuo X, Zhou Y, Smart T, Grossman D, Sanchez B. Electrical Characterization of Basal Cell Carcinoma Using a Handheld Electrical Impedance Dermography Device. JID Innov. 2021 Nov 26;2(1):100075. doi: 10.1016/j.xjidi.2021.100075. eCollection 2022 Jan. PMID 35072140
- BACKGROUNDWen-Ying Wong E, Pandeya S, Crandall H, Smart T, Dixon M, Boucher KM, Florell SR, Grossman D, Sanchez B. Electrical Impedance Dermography Differentiates Squamous Cell Carcinoma In Situ from Inflamed Seborrheic Keratoses. JID Innov. 2023 Feb 20;3(3):100194. doi: 10.1016/j.xjidi.2023.100194. eCollection 2023 May. PMID 37066115
- BACKGROUNDHansen NJ, Woodman K, Buoy S, Mao S, Barbon CEA, Lai SY, Fuller CD, Hutcheson KA, Sanchez B. Tongue electrical impedance myography correlates with functional, neurophysiologic, and clinical outcome measures in long-term oropharyngeal cancer survivors with and without hypoglossal neuropathy: An exploratory study. Head Neck. 2024 Mar;46(3):581-591. doi: 10.1002/hed.27618. Epub 2023 Dec 22. PMID 38133080